Therapeutic angiogenesis for critical limb ischemia

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Gene Therapy

Background:

• Critical limb ischemia (CLI) presents a significant unmet need for patients lacking revascularization options.
• Gene- and cell-based therapies offer a novel approach to promote angiogenesis for CLI treatment.
• Previous studies in animal models and early clinical trials suggest feasibility and short-term efficacy.

Purpose of the Study:

• To evaluate the potential of gene- and cell-based therapies for treating lower-limb critical limb ischemia (CLI).
• To assess the safety and efficacy of angiogenic growth factors and stem cells in CLI patients.
• To inform the design of ongoing and future clinical trials for novel CLI therapies.

Main Methods:

• Intramuscular injection of angiogenic tissue growth factors or bone marrow stem cells.
• Randomized clinical trials investigating safety and short-term efficacy.
• Phase III trials using hepatocyte growth factor gene or mesenchymal stem cells are ongoing.

Main Results:

• Demonstrated feasibility and short-term efficacy in clinical trials.
• Established safety profile with no observed off-target angiogenesis, tumor growth, or retinopathy progression.
• Current trials focus on patient selection, endpoints, and long-term outcomes.

Conclusions:

• Gene and cell therapies hold potential for CLI treatment, offering new revascularization strategies.
• Further research is needed to establish long-term efficacy and optimize delivery methods.
• Placebo-controlled, blinded trials with amputation-free survival as the primary endpoint are crucial for validation.